Cargando…
Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral Leishmaniasis
[Image: see text] A process suitable for kilogram-scale synthesis of (2R)-2-methyl-6-nitro-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-dihydroimidazo[2,1-b][1,3]oxazole (DNDI-VL-2098, 2), a preclinical drug candidate for the treatment of visceral leishmaniasis, is described. The four-step synthesis...
Autores principales: | Satam, Vijay S., Pedada, Srinivasa Rao, Kamaraj, Pasumpon, Antao, Nakita, Singh, Apoorva, Hindupur, Rama Mohan, Pati, Hari N., Thompson, Andrew M., Launay, Delphine, Martin, Denis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American
Chemical Society
2016
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437808/ https://www.ncbi.nlm.nih.gov/pubmed/28539754 http://dx.doi.org/10.1021/acs.oprd.6b00331 |
Ejemplares similares
-
DNDI-6148: A Novel
Benzoxaborole Preclinical Candidate
for the Treatment of Visceral Leishmaniasis
por: Mowbray, Charles E., et al.
Publicado: (2021) -
Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2019) -
Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis
por: Van Bocxlaer, Katrien, et al.
Publicado: (2021) -
Assessment of treatment outcomes of visceral leishmaniasis (VL) treated cases and impact of COVID-19 on VL management and control services in Bangladesh
por: Maruf, Shomik, et al.
Publicado: (2023) -
Screening and identification of potential inhibitor for visceral leishmaniasis (VL) through computational analysis
por: Shaslinah, N., et al.
Publicado: (2022)